PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Queensland Bauxite Limited (ASX:QBL) is most pleased to announce that the Company has received the formal approval letter for its application for reinstatement to the official list of ASX Limited.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the launch of the O2Vent(R) Optima device in Australia, an important addition to the Company's sleep treatment platform.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.
Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.
Oventus Medical Ltd (ASX:OVN) provides the Company's 2018 AGM Presentation.
